New Drug Discovery - Capabilities of Biologics Drug Development New Drug Discovery - Capabilities of Biologics Drug Development

Research & Development

Exploring arenas of development & analytical characterisation
Comprehensive Capabilities of Biologics Drug Development

Mankind ventured into the arena of biologics drug development in a focused manner with a well-defined strategy. A state-of-the-art research laboratory at our Integrated Research Centre houses latest equipment for process development and analytical characterization of highly complex biological drugs.

With a pool of talented scientists, the Mankind Biotechnology R&D has comprehensive capabilities for clone/cell line development, upstream and downstream process development, and analytical research.

Products based on recombinant proteins and mAbs are in focus for development of therapeutic products in the areas of auto-immune disorders, assisted reproductive therapy, and infertility treatment including other important disease areas.

Pipeline

Mankind's Drug Discovery Efforts are directed towards identifying and developing new therapies for disease areas that include Metabolic disorders, Liver and auto-immune disorders. Mankind’s focused and well-defined strategy has enabled us to identify promising candidates and we are building a robust pipeline of molecules for our pre-clinical and clinical developments. This steady movement will ensure that at least one compound enters the clinical phase in terms of first-in-human studies each year. New Drug Discovery and Research (NDDR) Department has capabilities to conduct drug discovery & development from concept to IND enabling pre-clinical and clinical studies

Metabolic Disorders:

Type 2 Diabetes Mellitus

Type 2 diabetes Mellitus (T2DM) is a chronic disease characterized by insulin resistance and pancreatic β-cell failure, with an underlying genetic predisposition that is heavily influenced by diet and lifestyle. NDDR’s discovery efforts are focusing on targets which can provide sustained glycemic control, with a focus on decreasing insulin resistance and preserving β-cell function.

Indication Hit to Lead Lead
Optimization
Candidate
Selection
IND Phase I Phase II Phase III
T2DM

Liver Diseases

Non-alcoholic Steatohepatitis (NASH) stems from the steady build-up of fat in the liver, which can trigger inflammation and, eventually, scarring and cirrhosis. Mankind’s research focuses on patients with late stage fibrosis due to NASH.

Indication Hit to Lead Lead
Optimization
Candidate
Selection
IND Phase I Phase II Phase III
NASH

Inflammation

Autoimmune disorders occur when a person’s immune system becomes unable to differentiate between normal and unhealthy cells, causing the immune system to attack the body’s healthy organs and tissues. We, at Mankind, are aiming for novel therapeutics which could have potential therapeutic effect on umbrella of inflammatory diseases.

Indication Hit to Lead Lead
Optimization
Candidate
Selection
IND Phase I Phase II Phase III
Auto- immune Disorder